Global HER-2 Positive Breast Cancer Market 2015-2019


#245342

123pages

Technavio

$ 3000

In Stock

 

About HER-2 Positive Breast Cancer

 

Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

 

TechNavio's analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.

 

Covered in this Report

 

This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients.

 

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

 

TechNavio's report, Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

 

Key Regions

 

  • Americas
  • APAC
  • EMEA  

     

Key Vendors

 

  • Celgene
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi

 

Other Prominent Vendors

 

  • Actavis
  • Array BioPharma
  • Biocad
  • Biocon
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Chugai Pharmaceutical
  • DARA BioSciences
  • EddingPharm
  • Eisai
  • Galena Biopharma
  • Halozyme Therapeutics
  • Hospira
  • Mylan
  • Oncothyreon
  • Pfizer
  • ProStrakan
  • Puma Biotechnology
  • Sun Pharmaceutical Industries
  • Synta Pharmaceuticals
  • Teva Pharmaceutical

 

Market Driver

 

  • Increase in Population of Breast Cancer Patients
  • For a full, detailed list, view our report

 

Market Challenge

 

  • Poor Diagnosis and Screening
  • For a full, detailed list, view our report

 

Market Trend

 

  • Increase in Awareness
  • For a full, detailed list, view our report

 

Key Questions Answered in this Report

 

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

 

01. Executive Summary

 

02. List of Abbreviations

 

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

 

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

 

05. Introduction

 

06. Disease Overview

06.1 Understanding the Disease

06.2 Pathophysiology

06.3 Epidemiology

06.4 Diagnosis

06.4.1 Immunohistochemistry

06.4.2 FISH

06.4.3 SPoT-Light HER2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)

06.4.4 Inform HER2 Dual ISH Test (Inform Dual In Situ Hybridization)

06.5 Management

06.5.1 Surgery

06.5.2 Radiotherapy

06.5.3 Chemotherapy

06.5.4 Targeted Therapy

06.5.5 Hormonal Therapy

06.6 Economic Burden

 

07. Pipeline Analysis

 

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 HER-2 Positive Breast Cancer Market in US

08.3.1 Market Size and Forecast

08.4 HER-2 Positive Breast Cancer Market in EU

08.4.1 Market Size and Forecast

08.5 Five Forces Analysis

 

09. Market Segmentation by Type of Therapy

09.1 Chemotherapy

09.1.1 Alkylating agents

09.1.2 Antimetabolites

09.1.3 Cytotoxic antibiotics

09.1.4 Taxanes

09.2 Targeted Therapy

09.3 Hormone Therapy

 

10. Market Segmentation by Molecule Type

 

10.1 Biologics

10.2 Small Molecules

 

11. Market Segmentation by Route of Administration

11.1 Oral

11.2 Parenteral

 

12. Geographical Segmentation

 

13. Buying Criteria

 

14. Market Growth Drivers

 

15. Drivers and their Impact

 

16. Market Challenges

 

17. Impact of Drivers and Challenges

 

18. Market Trends

 

19. Trends and their Impact

 

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2014

20.2.1 Competitive Assessment of the Top Drugs

20.2.2 Celgene

20.2.3 F. Hoffmann-La Roche

20.2.4 GlaxoSmithKline

20.2.5 Novartis

20.2.6 Sanofi

20.3 SWOT Analysis of the Targeted Therapies

20.3.1 Herceptin

20.3.2 Kadcyla

20.3.3 Perjeta

20.3.4 Tykerb

20.4 Other Prominent Vendors

 

21. Key Vendor Analysis

21.1 Celgene

21.1.1 Key Facts

21.1.2 Business Overview

21.1.3 Business Strategy

21.1.4 Business Segmentation by Revenue

21.1.5 Sales by Geography

21.1.6 Key Information

21.1.7 SWOT Analysis

21.2 F. Hoffmann-La Roche

21.2.1 Key Facts

21.2.2 Business Overview

21.2.3 Business Segmentation

21.2.4 Business Segmentation by Revenue 2012 and 2013

21.2.5 Sales by Geography

21.2.6 Business Strategy

21.2.7 Key Information

21.2.8 SWOT Analysis

21.3 GlaxoSmithKline

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Business Segmentation

21.3.4 Business Segmentation by Revenue 2012 and 2013

21.3.5 Sales by Geography

21.3.6 Pipeline Products

21.3.7 Business Strategy

21.3.8 Key Information

21.3.9 SWOT Analysis

21.4 Novartis

21.4.1 Key Facts

21.4.2 Business Description

21.4.3 Business Segmentation

21.4.4 Revenue by Business Segmentation

21.4.5 Revenue Comparison 2012 and 2013

21.4.6 Sales by Geography

21.4.7 Business Strategy

21.4.8 Key Developments

21.4.9 SWOT Analysis

21.5 Sanofi

21.5.1 Key Facts

21.5.2 Business Description

21.5.3 Business Segmentation

21.5.4 Revenue by Business Segmentation

21.5.5 Revenue Comparison 2012 and 2013

21.5.6 Sales by Geography

21.5.7 Business Strategy

21.5.8 Key Developments

21.5.9 SWOT Analysis

 

22. Other Reports in this Series

NA

 

Exhibit 1: Market Research Methodology
Exhibit 2: Executive Summary of Global HER-2 Positive Breast Cancer Market 2015-2019
Exhibit 3: Pathophysiology: HER-2 Positive Breast Cancer
Exhibit 4: Prevalence Data of HER-2 Positive Breast Cancer in the US, 2014
Exhibit 5: Diagnosis of HER-2 Positive Breast Cancer: IHC
Exhibit 6: Diagnosis of HER-2 Positive Breast Cancer: FISH
Exhibit 7: Management of HER-2 Positive Breast Cancer
Exhibit 8: ASCO Treatment Guidelines: HER-2 Positive Breast Cancer
Exhibit 9: Snapshot of Economic Burden of the HER-2 Positive Breast Cancer Market in US
Exhibit 10: Pipeline Snapshot: Combination Therapies
Exhibit 11: Pipeline Snapshot: Therapeutic Vaccines
Exhibit 12: Snapshot of Global HER-2 Positive Breast Cancer Market 2014
Exhibit 13: Global HER-2 Positive Breast Cancer Market 2014-2019 (US$ million)
Exhibit 14: Drivers and Challenges of the Global HER-2 Positive Breast Cancer Market
Exhibit 15: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
Exhibit 16: HER-2 Positive Breast Cancer Market in EU 2014-2019 (US$ million)
Exhibit 17: Global HER-2 Positive Breast Cancer Market Segmentation by Type of Therapy
Exhibit 18: Global HER-2 Positive Breast Cancer Market Segmentation by Type of Therapy 2014
Exhibit 19: Global HER-2 Positive Breast Cancer Market Segmentation by Molecule Type
Exhibit 20: Global HER-2 Positive Breast Cancer Market Segmentation by Molecule Type 2014
Exhibit 21: Global HER-2 Positive Breast Cancer Market Segmentation by Route of Administration
Exhibit 22: Global HER-2 Positive Breast Cancer Market Segmentation by Route of Administration 2014
Exhibit 23: Geographical Segmentation of Global HER-2 Positive Breast Cancer Market 2014
Exhibit 24: 5-Year Survival Rate by Stage of Diagnosis (SEER analysis for 2004-2010)
Exhibit 25: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer in 2013 (US$ million)
Exhibit 26: Product Portfolio: Celgene
Exhibit 27: YoY Growth Rate and Global Revenue of Abraxane 2010-2013 (US$ million)
Exhibit 28: Product Portfolio: F. Hoffmann-La Roche
Exhibit 29: YoY Growth Rate and Revenue of Herceptin 2010-2013 (US$ million)
Exhibit 30: Revenue of Perjeta for 2012-2013 (US$ million)
Exhibit 31: YoY Growth Rate and Revenue of Xeloda 2010-2013 (US$ million)
Exhibit 32: Product Portfolio: GlaxoSmithKline
Exhibit 33: YoY Growth Rate and Revenue of Tykerb 2010-2013 (US$ million)
Exhibit 34: Product Portfolio: Novartis
Exhibit 35: YoY Growth Rate and Revenue of Femara 2010-2013 (US$ million)
Exhibit 36: Product Portfolio: Sanofi
Exhibit 37: YoY Growth Rate and Global Revenue of Taxotere 2010-2013 (US$ million)
Exhibit 38: Herceptin: SWOT Analysis
Exhibit 39: Kadcyla: SWOT Analysis
Exhibit 40: Perjeta: SWOT Analysis
Exhibit 41: Tykerb: SWOT Analysis
Exhibit 42: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 43: Celgene: Sales by Geography 2013
Exhibit 44: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 45: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 46: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 47: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 48: GlaxoSmithKline: Business Segmentation 2013
Exhibit 49: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 50: GlaxoSmithKline: Sales by Geography 2013
Exhibit 51: GlaxoSmithKline: Pipeline Products 2013
Exhibit 52: Novartis AG: Business Segmentation
Exhibit 53: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 54: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 55: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 56: Sanofi SA: Business Segmentation
Exhibit 57: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 58: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 59: Sanofi SA: Sales Revenue by Geographical Segmentation 2013